In another study, high levels of reduced TXN caused the failure of trastuzumab to activate phosphatase and tensin homolog (PTEN), and TXN inhibition was required for sensitization of breast cancer cells resistant to anti-HER2 therapy. This evidence concerns the gene PTEN and breast carcinoma.